These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 10940274

  • 21. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
    Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B.
    Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
    [Abstract] [Full Text] [Related]

  • 22. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1.
    Wishart JM, Horowitz M, Morris HA, Jones KL, Nauck MA.
    Peptides; 1998; 19(6):1049-53. PubMed ID: 9700754
    [Abstract] [Full Text] [Related]

  • 23. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.
    Schjoldager BT, Mortensen PE, Christiansen J, Orskov C, Holst JJ.
    Dig Dis Sci; 1989 May; 34(5):703-8. PubMed ID: 2714145
    [Abstract] [Full Text] [Related]

  • 24. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M.
    J Clin Invest; 1998 Apr 01; 101(7):1421-30. PubMed ID: 9525985
    [Abstract] [Full Text] [Related]

  • 25. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon.
    Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Staun M, Mortensen PB.
    Scand J Gastroenterol; 2002 Apr 01; 37(4):392-8. PubMed ID: 11989828
    [Abstract] [Full Text] [Related]

  • 26. Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes.
    Thomsen C, Storm H, Holst JJ, Hermansen K.
    Am J Clin Nutr; 2003 Mar 01; 77(3):605-11. PubMed ID: 12600850
    [Abstract] [Full Text] [Related]

  • 27. Role of glucagon-like peptide-2 deficiency in neonatal short-bowel syndrome using neonatal piglets.
    Hua Z, Turner JM, Sigalet DL, Wizzard PR, Nation PN, Mager DR, Ball RO, Pencharz PB, Wales PW.
    Pediatr Res; 2013 Jun 01; 73(6):742-9. PubMed ID: 23481550
    [Abstract] [Full Text] [Related]

  • 28. Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period.
    Padidela R, Patterson M, Sharief N, Ghatei M, Hussain K.
    Eur J Endocrinol; 2009 Jan 01; 160(1):53-8. PubMed ID: 18952761
    [Abstract] [Full Text] [Related]

  • 29. The influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concentration in man.
    Robertson MD, Livesey G, Morgan LM, Hampton SM, Mathers JC.
    J Endocrinol; 1999 Apr 01; 161(1):25-31. PubMed ID: 10194525
    [Abstract] [Full Text] [Related]

  • 30. Systemic GLP-2 levels do not limit adaptation after distal intestinal resection.
    Topstad D, Martin G, Sigalet D.
    J Pediatr Surg; 2001 May 01; 36(5):750-4. PubMed ID: 11329581
    [Abstract] [Full Text] [Related]

  • 31. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility.
    MacIntosh CG, Andrews JM, Jones KL, Wishart JM, Morris HA, Jansen JB, Morley JE, Horowitz M, Chapman IM.
    Am J Clin Nutr; 1999 May 01; 69(5):999-1006. PubMed ID: 10232642
    [Abstract] [Full Text] [Related]

  • 32. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate.
    Holst JJ, Hartmann B, Gottschalck IB, Jeppesen PB, Miholic J, Henriksen DB.
    Scand J Gastroenterol; 2007 Jul 01; 42(7):814-20. PubMed ID: 17558904
    [Abstract] [Full Text] [Related]

  • 33. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jun 01; 88(6):2706-13. PubMed ID: 12788877
    [Abstract] [Full Text] [Related]

  • 34. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1.
    Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ.
    Scand J Gastroenterol; 2004 Apr 01; 39(4):353-8. PubMed ID: 15125467
    [Abstract] [Full Text] [Related]

  • 35. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH.
    J Clin Endocrinol Metab; 2002 Mar 01; 87(3):1239-46. PubMed ID: 11889194
    [Abstract] [Full Text] [Related]

  • 36. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
    Vilsbøll T, Agersø H, Krarup T, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jan 01; 88(1):220-4. PubMed ID: 12519856
    [Abstract] [Full Text] [Related]

  • 37. GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat.
    Bozkurt A, Näslund E, Holst JJ, Hellström PM.
    Regul Pept; 2002 Jul 15; 107(1-3):129-35. PubMed ID: 12137975
    [Abstract] [Full Text] [Related]

  • 38. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs.
    Fung LC, Chisholm C, Greenberg GR.
    Endocrinology; 1998 Jan 15; 139(1):189-94. PubMed ID: 9421414
    [Abstract] [Full Text] [Related]

  • 39. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA, Siemsglüss J, Orskov C, Holst JJ.
    Z Gastroenterol; 1996 Mar 15; 34(3):159-66. PubMed ID: 8650968
    [Abstract] [Full Text] [Related]

  • 40. No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man.
    Long SJ, Sutton JA, Amaee WB, Giouvanoudi A, Spyrou NM, Rogers PJ, Morgan LM.
    Br J Nutr; 1999 Apr 15; 81(4):273-9. PubMed ID: 10999014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.